Prevalence and predictors of hepatic steatosis in adults with newly diagnosed chronic liver disease due to hepatitis C

Amanda V. Hayman, Andre N. Sofair, M. Michele Manos, Ann Thomas, Norah Terrault, Grace Van Ness, Nicole Stabach, Marie Robert, Gregory Rumore, Christopher Corless, Beth Bell, Stephanie Bialek, Atif Zaman

Research output: Contribution to journalArticle

5 Citations (Scopus)

Abstract

Obesity appears to be a risk factor for hepatic steatosis, which has been implicated in the development of hepatic fibrosis in patients with hepatitis C virus infection. We conducted the current study to examine whether obesity is associated with hepatic steatosis among patients with chronic hepatitis C identified from a population-based cohort.Study participants were persons with chronic hepatitis C who had had a liver biopsy, identified from a population-based study of persons with newly identified chronic liver disease conducted in gastroenterology practices. Data were collected through patient interviews, medical record abstraction, and review of previously performed liver biopsies. The outcome variable of interest was significant steatosis, defined as steatosis grade 2 determined from liver biopsy samples. Univariate and multivariate analyses were performed using logistic regression techniques.The analysis included 450 patients with chronic hepatitis C with available liver biopsy slides. Overall, only 15.8% of subjects had significant hepatic steatosis (grade-2), while 35.9% of obese subjects had significant steatosis. In multivariate analysis, significant fibrosis (defined as-grade 2) (odds ratio [OR], 3.43; 95% confidence interval [CI], 1.59-7.37), obesity (OR, 3.32; 95% CI, 1.84-5.98), genotype 3 (OR, 2.5; 95% CI, 1.09-5.75), and the presence of multiple metabolic comorbidities (OR, 1.91; 95% CI, 0.88-4.11) were independently associated with steatosis.In this unique United States cohort of patients with newly diagnosed chronic liver disease due to hepatitis C, obesity was independently associated with hepatic steatosis. The results of this study provide additional evidence that obesity worsens liver damage in patients with chronic hepatitis C, and suggest a role for weight loss as a treatment modality in these patients.

Original languageEnglish (US)
Pages (from-to)302-306
Number of pages5
JournalMedicine
Volume88
Issue number5
DOIs
StatePublished - Sep 2009

Fingerprint

Hepatitis C
Liver Diseases
Chronic Disease
Liver
Chronic Hepatitis C
Obesity
Odds Ratio
Confidence Intervals
Biopsy
Fibrosis
Multivariate Analysis
Gastroenterology
Virus Diseases
Hepacivirus
Population
Medical Records
Comorbidity
Weight Loss
Logistic Models
Genotype

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Prevalence and predictors of hepatic steatosis in adults with newly diagnosed chronic liver disease due to hepatitis C. / Hayman, Amanda V.; Sofair, Andre N.; Manos, M. Michele; Thomas, Ann; Terrault, Norah; Ness, Grace Van; Stabach, Nicole; Robert, Marie; Rumore, Gregory; Corless, Christopher; Bell, Beth; Bialek, Stephanie; Zaman, Atif.

In: Medicine, Vol. 88, No. 5, 09.2009, p. 302-306.

Research output: Contribution to journalArticle

Hayman, AV, Sofair, AN, Manos, MM, Thomas, A, Terrault, N, Ness, GV, Stabach, N, Robert, M, Rumore, G, Corless, C, Bell, B, Bialek, S & Zaman, A 2009, 'Prevalence and predictors of hepatic steatosis in adults with newly diagnosed chronic liver disease due to hepatitis C', Medicine, vol. 88, no. 5, pp. 302-306. https://doi.org/10.1097/MD.0b013e3181b954f4
Hayman, Amanda V. ; Sofair, Andre N. ; Manos, M. Michele ; Thomas, Ann ; Terrault, Norah ; Ness, Grace Van ; Stabach, Nicole ; Robert, Marie ; Rumore, Gregory ; Corless, Christopher ; Bell, Beth ; Bialek, Stephanie ; Zaman, Atif. / Prevalence and predictors of hepatic steatosis in adults with newly diagnosed chronic liver disease due to hepatitis C. In: Medicine. 2009 ; Vol. 88, No. 5. pp. 302-306.
@article{d7dfae82ed5e4d35a78d1a3e69c4b7c2,
title = "Prevalence and predictors of hepatic steatosis in adults with newly diagnosed chronic liver disease due to hepatitis C",
abstract = "Obesity appears to be a risk factor for hepatic steatosis, which has been implicated in the development of hepatic fibrosis in patients with hepatitis C virus infection. We conducted the current study to examine whether obesity is associated with hepatic steatosis among patients with chronic hepatitis C identified from a population-based cohort.Study participants were persons with chronic hepatitis C who had had a liver biopsy, identified from a population-based study of persons with newly identified chronic liver disease conducted in gastroenterology practices. Data were collected through patient interviews, medical record abstraction, and review of previously performed liver biopsies. The outcome variable of interest was significant steatosis, defined as steatosis grade 2 determined from liver biopsy samples. Univariate and multivariate analyses were performed using logistic regression techniques.The analysis included 450 patients with chronic hepatitis C with available liver biopsy slides. Overall, only 15.8{\%} of subjects had significant hepatic steatosis (grade-2), while 35.9{\%} of obese subjects had significant steatosis. In multivariate analysis, significant fibrosis (defined as-grade 2) (odds ratio [OR], 3.43; 95{\%} confidence interval [CI], 1.59-7.37), obesity (OR, 3.32; 95{\%} CI, 1.84-5.98), genotype 3 (OR, 2.5; 95{\%} CI, 1.09-5.75), and the presence of multiple metabolic comorbidities (OR, 1.91; 95{\%} CI, 0.88-4.11) were independently associated with steatosis.In this unique United States cohort of patients with newly diagnosed chronic liver disease due to hepatitis C, obesity was independently associated with hepatic steatosis. The results of this study provide additional evidence that obesity worsens liver damage in patients with chronic hepatitis C, and suggest a role for weight loss as a treatment modality in these patients.",
author = "Hayman, {Amanda V.} and Sofair, {Andre N.} and Manos, {M. Michele} and Ann Thomas and Norah Terrault and Ness, {Grace Van} and Nicole Stabach and Marie Robert and Gregory Rumore and Christopher Corless and Beth Bell and Stephanie Bialek and Atif Zaman",
year = "2009",
month = "9",
doi = "10.1097/MD.0b013e3181b954f4",
language = "English (US)",
volume = "88",
pages = "302--306",
journal = "Medicine; analytical reviews of general medicine, neurology, psychiatry, dermatology, and pediatries",
issn = "0025-7974",
publisher = "Lippincott Williams and Wilkins",
number = "5",

}

TY - JOUR

T1 - Prevalence and predictors of hepatic steatosis in adults with newly diagnosed chronic liver disease due to hepatitis C

AU - Hayman, Amanda V.

AU - Sofair, Andre N.

AU - Manos, M. Michele

AU - Thomas, Ann

AU - Terrault, Norah

AU - Ness, Grace Van

AU - Stabach, Nicole

AU - Robert, Marie

AU - Rumore, Gregory

AU - Corless, Christopher

AU - Bell, Beth

AU - Bialek, Stephanie

AU - Zaman, Atif

PY - 2009/9

Y1 - 2009/9

N2 - Obesity appears to be a risk factor for hepatic steatosis, which has been implicated in the development of hepatic fibrosis in patients with hepatitis C virus infection. We conducted the current study to examine whether obesity is associated with hepatic steatosis among patients with chronic hepatitis C identified from a population-based cohort.Study participants were persons with chronic hepatitis C who had had a liver biopsy, identified from a population-based study of persons with newly identified chronic liver disease conducted in gastroenterology practices. Data were collected through patient interviews, medical record abstraction, and review of previously performed liver biopsies. The outcome variable of interest was significant steatosis, defined as steatosis grade 2 determined from liver biopsy samples. Univariate and multivariate analyses were performed using logistic regression techniques.The analysis included 450 patients with chronic hepatitis C with available liver biopsy slides. Overall, only 15.8% of subjects had significant hepatic steatosis (grade-2), while 35.9% of obese subjects had significant steatosis. In multivariate analysis, significant fibrosis (defined as-grade 2) (odds ratio [OR], 3.43; 95% confidence interval [CI], 1.59-7.37), obesity (OR, 3.32; 95% CI, 1.84-5.98), genotype 3 (OR, 2.5; 95% CI, 1.09-5.75), and the presence of multiple metabolic comorbidities (OR, 1.91; 95% CI, 0.88-4.11) were independently associated with steatosis.In this unique United States cohort of patients with newly diagnosed chronic liver disease due to hepatitis C, obesity was independently associated with hepatic steatosis. The results of this study provide additional evidence that obesity worsens liver damage in patients with chronic hepatitis C, and suggest a role for weight loss as a treatment modality in these patients.

AB - Obesity appears to be a risk factor for hepatic steatosis, which has been implicated in the development of hepatic fibrosis in patients with hepatitis C virus infection. We conducted the current study to examine whether obesity is associated with hepatic steatosis among patients with chronic hepatitis C identified from a population-based cohort.Study participants were persons with chronic hepatitis C who had had a liver biopsy, identified from a population-based study of persons with newly identified chronic liver disease conducted in gastroenterology practices. Data were collected through patient interviews, medical record abstraction, and review of previously performed liver biopsies. The outcome variable of interest was significant steatosis, defined as steatosis grade 2 determined from liver biopsy samples. Univariate and multivariate analyses were performed using logistic regression techniques.The analysis included 450 patients with chronic hepatitis C with available liver biopsy slides. Overall, only 15.8% of subjects had significant hepatic steatosis (grade-2), while 35.9% of obese subjects had significant steatosis. In multivariate analysis, significant fibrosis (defined as-grade 2) (odds ratio [OR], 3.43; 95% confidence interval [CI], 1.59-7.37), obesity (OR, 3.32; 95% CI, 1.84-5.98), genotype 3 (OR, 2.5; 95% CI, 1.09-5.75), and the presence of multiple metabolic comorbidities (OR, 1.91; 95% CI, 0.88-4.11) were independently associated with steatosis.In this unique United States cohort of patients with newly diagnosed chronic liver disease due to hepatitis C, obesity was independently associated with hepatic steatosis. The results of this study provide additional evidence that obesity worsens liver damage in patients with chronic hepatitis C, and suggest a role for weight loss as a treatment modality in these patients.

UR - http://www.scopus.com/inward/record.url?scp=70349659663&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=70349659663&partnerID=8YFLogxK

U2 - 10.1097/MD.0b013e3181b954f4

DO - 10.1097/MD.0b013e3181b954f4

M3 - Article

C2 - 19745689

AN - SCOPUS:70349659663

VL - 88

SP - 302

EP - 306

JO - Medicine; analytical reviews of general medicine, neurology, psychiatry, dermatology, and pediatries

JF - Medicine; analytical reviews of general medicine, neurology, psychiatry, dermatology, and pediatries

SN - 0025-7974

IS - 5

ER -